GSK Valtrex gains indication, another pending
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline's Valtrex (valacyclovir) clears FDA for suppression of recurrent genital herpes in HIV-infected patients April 1. FDA's Antiviral Drugs Advisory Committee will consider another supplemental indication for Valtrex May 14 - use as suppressive therapy to reduce the risk of transmitting genital herpes. GSK submitted the risk reduction sNDA Oct. 31, 2002 and expects a standard revie
You may also be interested in...
Valtrex transmission indication
FDA's Aug. 29 approval of GSK's Valtrex (valacyclovir) for reduction of the risk of heterosexual transmission of genital herpes in immunocompetent patients follows the Antiviral Drugs Advisory Committee's May 14 recommendation on restricting the patient population. GSK had been seeking a broader indication that did not specify sexual orientation or immune status. The company is developing a patient education brochure, to be available in October, emphasizing safe-sex practices with the use of Valtrex. FDA cleared the agent April 1 for suppression of recurrent genital herpes in HIV-infected patients (1Pharmaceutical Approvals Monthly April 1, 2003, In Brief)...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.